Life Sciences

  • October 19, 2026

    5th Circ. Unwinds Cassava Class Over 'Meme Stock' Claims

    The Fifth Circuit has overturned the class status of investors accusing Cassava Sciences Inc. of making misleading statements about clinical trial results for a potential Alzheimer's drug, saying that a lower court judge did not properly consider the company's arguments that its stock price was impacted by the "meme stock" craze.

  • October 19, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week blocked Cloudflare Inc. from completing a restructuring meant to preserve its founders' voting control, while Tower Semiconductor Ltd. accused Intel Corp. of backing out of a semiconductor manufacturing agreement and social media company Triller Group Inc. challenged its removal from Nasdaq.

  • October 19, 2026

    Prior 5th Amendment Pleadings Complicate Mylan Testimony

    Mylan can use deposition testimony from one current and one former executive in next year's price-fixing trial, a Connecticut federal judge ruled Friday, but state attorneys general can bring up the company "pulling the strings" in the witnesses' decision to testify after originally invoking the Fifth Amendment.

  • October 19, 2026

    DOJ Appeals New Trial Order In Ex-NFL Player's Fraud Case

    The U.S. Department of Justice said it's asking the Fifth Circuit to review a Texas federal judge's decision to grant a new trial for a former NFL player convicted in a $328 million Medicare billing scheme.

  • October 19, 2026

    A&O Shearman, Cooley Guide Merck's $1.3B UK Biotech Deal

    Germany's Merck said Monday it has agreed to acquire U.K. biotechnology company Silence Therapeutics PLC at a $1.3 billion equity value, with Allen Overy Shearman Sterling advising Merck and Cooley LLP representing Silence Therapeutics.

  • October 19, 2026

    Full Fed. Circ. Won't Revive Insulet's $59M Trade Secrets Win

    The Federal Circuit will not reinstate a jury's $59.4 million trade secret theft verdict against EOFlow Co. Ltd., rejecting insulin product developer Insulet Corp.'s request for rehearing of a panel decision overturning the award.

  • October 16, 2026

    2nd Circ. Denies Rehearing In Tylenol Autism Suits

    The Second Circuit on Friday denied a bid by Tylenol maker Kenvue and several retailers to reconsider its ruling that a district court improperly excluded expert testimony for plaintiffs who claim prenatal exposure to the over-the-counter pain reliever causes autism and ADHD.

  • October 16, 2026

    Suing The Trump Admin Can Have Massive Impact, Attys Say

    Lawyers representing clients against the federal government spoke Friday about the challenges and rewards of such litigation in the Trump era, with plaintiff-side powerhouse Elizabeth Cabraser pointing to the potential for massive impact, including one case in which she successfully got more than a billion dollars in grant funding reinstated.

  • October 16, 2026

    Device Co. Accused Of Shorting Co-Founder's Payments

    The co-founder of a company that sells medical devices told a Colorado state court Thursday that the company lowered the percentage he is owed of $7.7 million in outstanding receivables from a client without approval.

  • October 16, 2026

    Quarterly IPO Volume Fell Short Of Expectations Amid Delays

    Third-quarter capital markets activity in the U.S. proved to be robust with a solid string of initial public offerings, but capital markets attorneys say it did not fully meet expectations due to delays of notable IPOs caused by market uncertainty.

  • October 16, 2026

    FTC Wants More Info On $350M Surgical Supplies Deal

    The Federal Trade Commission has requested additional information about MiMedx Group Inc.'s planned $350 million purchase of Sanara MedTech Inc., a company that develops and commercializes products for use during surgery.

  • October 16, 2026

    City Therapeutics' Upsized $200M IPO Joins Biotech Wave

    Blood clot-focused biotechnology firm City Therapeutics began trading publicly Friday after raising $200 million in its upsized initial public offering steered by Goodwin Procter LLP and Cooley LLP, joining a wave of biotechnology public listings over the past few weeks.

  • October 16, 2026

    Could A Criminal Sentencing Case Upend Loper Bright?

    U.S. Supreme Court Justice Neil Gorsuch is concerned that a ruling instructing trial courts to defer to the U.S. Sentencing Commission's interpretation of federal sentencing guidelines could blow a "pretty big hole" in the court's recent rejection of deference doctrines. His colleagues, however, don't appear as perturbed.

  • October 16, 2026

    States Win 1st OK Of $400M Sandoz Generic Price-Fixing Deal

    A Connecticut federal judge granted preliminary approval Friday to a $400 million settlement between a coalition of states, Sandoz Inc. and its subsidiary Fougera Pharmaceuticals Inc. over allegations of generic drug price-fixing and market allocation, setting aside $280 million as restitution.

  • October 16, 2026

    Contradictory Contract Dooms Pot Co.'s Injunction Bid

    A California state judge has rejected a cannabis genetics company's bid for an injunction against a former business partner in a contract dispute, saying the contract's self-contradictory provisions make it unclear that the company is entitled to retrieve its cannabis strains.

  • October 16, 2026

    EpicentRx, Ex-Secretary Clash In Del. Over 5th Contempt Bid

    EpicentRx's former corporate secretary urged the Delaware Chancery Court on Friday to impose a partial default judgment against the biotechnology firm and appoint a receiver, arguing it has continued to ignore advancement and contempt orders. Meanwhile, the company countered that those remedies would be disproportionate to what it says is ultimately a dispute over unpaid money.

  • October 16, 2026

    Taxation With Representation: Freshfields, Morgan Lewis

    In this week's Taxation With Representation, Penske Automotive Group Inc. agrees to be taken private by Motown Acquisition Corp., a GTCR-led group of private investment firms acquires software firm CCC Intelligent Solutions Holdings Inc. and a Steris PLC subsidiary buys specialty surgical products business Xodus Medical Inc.

  • October 16, 2026

    Expect These Post-Midterm Probes If The Hill Changes Hands

    The top investigative priorities of a potentially Democratic-controlled Congress are coming into sharper focus with the midterms weeks away and could impact an array of companies and individuals in technology, finance and energy, experts say.

  • October 16, 2026

    Mayer Brown Lands 2 Sheppard FDA Partners

    Mayer Brown LLP has bolstered its life sciences capabilities with two former Sheppard partners, including that firm's former U.S. Food and Drug Administration practice leader.

  • October 16, 2026

    Mayne Settles US Patent Suit With Teva Over Generic Imvexxy

    ASX-listed Mayne Pharma announced on Friday another settlement related to its oestradiol vaginal insert Imvexxy, with medicines maker Teva Pharmaceuticals USA Inc. agreeing not to enter the U.S. market with a generic version until 2032.

  • October 15, 2026

    OptumHealth Can't Get Out Of PBM Cases In Opioid MDL

    The healthcare delivery arm of UnitedHealth Group's Optum division can't escape bellwether cases alleging pharmacy benefit managers contributed to the opioid epidemic, an Ohio federal judge ruled Thursday, finding a recent Sixth Circuit decision didn't alter the court's jurisdiction over related state-law claims.

  • October 15, 2026

    OrbiMed Closes 2 Latest Funds With Combined $3B In Tow

    Healthcare-focused investment firm OrbiMed on Thursday revealed that it has secured $3 billion of investor commitments across its two latest private equity funds.

  • October 15, 2026

    Medical AI Platforms Report Settlement Amid Discovery Battle

    Medical artificial intelligence startup OpenEvidence and competitors Doximity Inc. and Pathway Medical Inc. told a Massachusetts federal judge on Thursday that they have reached a settlement in principle to resolve a contentious lawsuit and counterclaim.

  • October 15, 2026

    PhRMA Again Seeks To Join 340B Rebate Pilot Fight

    The Pharmaceutical Research and Manufacturers of America on Thursday asked a Maine federal court to let it join a lawsuit challenging the Trump administration's proposed rebate system in the 340B drug discount program, arguing the litigation could directly affect its members' approved plans and financial interests.

  • October 15, 2026

    For 2nd Time, PTAB Won't Invalidate Claims In DNA Patent

    The Patent Trial and Appeal Board has once again found that Guardant Health couldn't show that claims in a University of Washington DNA sequencing patent that had been part of a $245 million infringement judgment were invalid.

Expert Analysis

  • Where DOJ's Fraud Directive May Actually Affect Enforcement

    Author Photo

    The U.S. Department of Justice’s recent directive outlining corporate fraud enforcement priorities is mostly a management document instead of a policy, but one part may actually undermine the directive's goals by leading to worse outcomes for organizational defendants and less corporate self-disclosure, says Zachary Warren at Williams & Connolly.

  • Why Vaccine Court Inoculates Drugmakers Against Litigation

    Author Photo

    Most claimants alleging injuries from routine childhood vaccines must complete an administrative compensation proceeding before they can sue in civil court — and recent legislative efforts aimed at weakening vaccine manufacturers' legal protections do not account for the important reasons the existing framework was put in place, say attorneys at Goldman Ismail.

  • What Lawyers Should Know Before Accepting Crypto Payment

    Author Photo

    As clients increasingly request to pay legal fees, retainers and escrow funds using cryptocurrency, lawyers should consider how only a handful of state bar authorities have addressed the issue with varying ethics opinions, as well as the related questions that no authority has yet answered, says attorney Felix Shipkevich.

  • What To Know As State 'Neural Data' Privacy Laws Emerge

    Author Photo

    Attorneys at Goodwin discuss new state laws aimed at regulating consumer data generated from nervous system activity, explain why neurotechnology is attracting state and federal legislators’ attention, and highlight the compliance obligations that industry players should address now.

  • Data Sale In Spirit Bankruptcy Raises Novel Privacy Risks

    Author Photo

    Spirit Airlines' planned sale of deidentified business data to Google for artificial intelligence training exposes gaps in the Bankruptcy Code's privacy guardrails, particularly for employee information, say attorneys at Patterson Belknap.

  • IDScan Data Breach Puts Spotlight On Vendor Oversight

    Author Photo

    A recently reported breach that exposed millions of identification documents held by IDScan.net highlights the liability risks for businesses that contract with third-party identity processors, and emphasizes the importance of auditing vendors' data retention practices, say attorneys at Tucker Ellis.

  • Series

    Mentalism Makes Me A Better Lawyer

    Author Photo

    Convincing strangers I can read their minds may seem like an unusual second career for a legal practitioner, but both disciplines share several important requirements, including trust and preparation, says Warren Biro at Manatt.

  • Why And How To Build A Neurodiversity-Informed Practice

    Author Photo

    By better understanding neurodiversity and implementing simple accommodations for clients with autism, ADHD or learning differences, attorneys can build stronger relationships with those who may otherwise struggle to obtain and benefit from legal services, while developing good habits that will benefit everyone they represent, says Ting Cheung at Sanford Heisler.

  • Opinion

    PTAB Panels Should Revamp Their IPR Merits Decisions

    Author Photo

    In light of U.S. Patent and Trademark Office Director John Squires' recent announcement about returning merits institution determinations to the Patent Trial and Appeal Board, the implementing framework should strengthen PTAB panels' responsibility for the benefit of both petitioners and patent owners, says Brandon Theiss at AddyHart.

  • Patent Eligibility Bulletin: Claim Solutions, Not Results

    Author Photo

    In the third quarter of the year, two Federal Circuit decisions illustrated that claims sharing the same disclosure can fall on opposite sides of the patent eligibility line, depending on the specific nuances of tech patents' claims, says Reilley Keane at Banner Witcoff.

  • Abbott FCA Deal Shows Enforcement Adequacy Quandaries

    Author Photo

    Abbott Laboratories’ recent False Claims Act resolution illustrates several tricky questions that both prosecutors and defense counsel must address when weighing whether a civil enforcement action alone adequately addresses allegedly wrongful conduct, says James Koukios at MoFo.

  • New DNA Screening Standard Has No Clear Playbook

    Author Photo

    Although the government has not yet released promised guidance intended to support its new standards for screening mail-order DNA, companies should not read this as a reprieve from the Oct. 13 compliance deadline because the delay shifts enforcement risk to statutes that need no new authority, including false statements, the False Claims Act and fraud, says Ashwin Ram at Buchalter.

  • Series

    Mich. Banking Brief: All The Notable Legal Updates In Q3

    Author Photo

    We are at an inflection point for Michigan financial services law, with a state Supreme Court decision recently overruling more than 25 years of precedent on the Michigan Consumer Protection Act, and pending legislation that could significantly shift the regulatory landscape, say attorneys and advisers at Dykema.

  • Testing AI's Promise For Large-Scale Document Review

    Author Photo

    Our document-review comparison of attorneys' responsiveness and issue coding decisions versus predictions generated by artificial intelligence across 1,600 documents suggests that these tools can offer a reasonable and reliable basis for improved discovery workflows, provided lawyers understand where guardrails are needed, say attorneys at Redgrave.

  • AG Watch: Va. Vape Product Regulations Enter A New Phase

    Author Photo

    Virginia's new vape enforcement framework carries important implications related to product eligibility and certification requirements for businesses operating in the marketplace, representing the culmination of several years of legislative action, regulatory development, litigation and interagency planning, says Chuck Slemp at Cozen O'Connor.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here